David Singleton

Mr. David Singleton

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Journal of NeuroEngineering and Rehabilitation
Verified
Journal Article
Open access
PDF file
KSKirsty Scott
Kirsty Scott
TBTecla Bonci
Tecla Bonci
FSFrancesca Salis
Francesca Salis
Lisa AlcockLisa Alcock
Lisa Alcock
EBEllen Buckley
Ellen Buckley
Claudia MazzàClaudia Mazzà
Claudia Mazzà
Background: Measuring mobility in daily life entails dealing with confounding factors arising from multiple sources, including pathological characteristics, patient specific walking strategies, environment/context, and purpose of the task. The primary aim of this study is to propose and validate a protocol for simulating real-world gait accounting for all these factors within a single set of observations, while ensuring minimisation of participant burden and safety. Methods: The protocol included eight motor tasks at varying speed, incline/steps, surface, path shape, cognitive demand, and included postures that may abruptly alter the participants’ strategy of walking. It was deployed in a convenience sample of 108 participants recruited from six cohorts that included older healthy adults (HA) and participants with potentially altered mobility due to Parkinson’s disease (PD), multiple sclerosis (MS), proximal femoral fracture (PFF), chronic obstructive pulmonary disease (COPD) or congestive heart failure (CHF). A novelty introduced in the protocol was the tiered approach to increase difficulty both within the same task (e.g., by allowing use of aids or armrests) and across tasks. Results: The protocol proved to be safe and feasible (all participants could complete it and no adverse events were recorded) and the addition of the more complex tasks allowed a much greater spread in walking speeds to be achieved compared to standard straight walking trials. Furthermore, it allowed a representation of a variety of daily life relevant mobility aspects and can therefore be used for the validation of monitoring devices used in real life. Conclusions: The protocol allowed for measuring gait in a variety of pathological conditions suggests that it can also be used to detect changes in gait due to, for example, the onset or progression of a disease, or due to therapy. Trial registration: ISRCTN—12246987.

26 December 2025 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
AYAlison Yarnall
Alison Yarnall
LALisa Alcock
Lisa Alcock
CSChristian Schlenstedt
Christian Schlenstedt
CAClaudia Armengol
Claudia Armengol
CBClemens Becker
Clemens Becker
WMWalter Maetzler
Walter Maetzler
Background: A key challenge in trials targeting disease modification in Parkinson's disease (PD) is the lack of sensitive, precise, and patient-relevant outcome measures. Digital mobility outcomes (DMOs), captured using body-worn devices, offer a novel, objective means to assess real-world gait and mobility—domains often impaired early in PD. The Mobilise-D consortium was established to develop and validate DMOs in PD and other conditions. Objective: To describe DMOs in a large, representative international cohort of individuals with PD and compare to controls and across disease stage; and to determine compliance and feasibility. Methods: As part of the Mobilise-D Clinical Validation and Extension Studies, real-world mobility of individuals with PD (n = 601) and matched controls (n = 232) was assessed using a single wearable device for seven days. Data were processed to yield 24 technically validated DMOs, representing different domains of real-world walking and mobility performance. Results: DMO data were available for 531 PD and 221 controls. Significant differences between the groups were observed in 20 of 24 DMOs. Compared to controls, PD participants exhibited shorter daily walking duration and lower step counts, walking at a higher cadence and in fewer walking bouts per day. Findings also varied by disease severity, with differences observed particularly between controls vs. mild (Hoehn and Yahr stage I-II) and mild vs. moderate (Hoehn and Yahr stage III) disease. Compliance rates were high. Conclusions: Distinct DMO patterns across PD severity and between PD and controls support their utility as sensitive, scalable outcome measures for future clinical trials and therapeutic development.

28 August 2019 in JMIR Research Protocols
Verified
Journal Article
Open access
EGEstefania Guisado-Fernandez
Estefania Guisado-Fernandez
Brian CaulfieldBrian Caulfield
Brian Caulfield
Paula Alexandra SilvaPaula Alexandra Silva
Paula Alexandra Silva
LMLaura Mackey
Laura Mackey
DSDavid Singleton
David Singleton
CBCatherine Blake
Catherine Blake
Background: Dementia disease is a chronic condition that leads a person with dementia (PwD) into a state of progressive deterioration and a greater dependence in performing their activities of daily living (ADL). It is believed nowadays that PwDs and their informal caregivers can have a better life when provided with the appropriate services and support. Connected Health (CH) is a new technology-enabled model of chronic care delivery where the stakeholders are connected through a health portal, ensuring continuity and efficient flow of information. CH has demonstrated promising results regarding supporting informal home care and Aging in Place, and it has been increasingly considered by researchers and health care providers as a method for dementia home care management. Objective: This study aims to describe the development and implementation protocol of a CH platform system to support informal caregivers of PwDs at home. Methods: This is a longitudinal observational mixed methods study where quantitative and qualitative data will be combined for determining the utility of the CH platform for dementia home care. Dyads, consisting of a PwD and their informal caregiver living in the community, will be divided into 2 groups: the intervention group, which will receive the CH technology package at home, and the usual care group, which will not have any CH technology at all. Dyads will be followed up for 12 months during which they will continue with their traditional care plan, but in addition, the intervention group will receive the CH package for their use at home during 6 months (months 3 to 9 of the yearly follow-up). Further comprehensive assessments related to the caregiver’s and PwD’s emotional and physical well-being will be performed at the initial assessment and at 3, 6, 9, and 12 months using international and standardized validated questionnaires and semistructured individual interviews. Results: This 3-year funded study (2016-2019) is currently in its implementation phase and is expected to finish by December 2019. We believe that CH can potentially change the PwD current care model, facilitating a proactive and preventive model, utilizing self-management–based strategies, and enhancing caregivers’ involvement in the management of health care at home for PwDs. Conclusions: We foresee that our CH platform will provide knowledge and promote autonomy for the caregivers, which may empower them into greater control of the care for PwDs, and with it, improve the quality of life and well-being for the person they are caring for and for themselves through a physical and cognitive decline predictive model. We also believe that facilitating information sharing between all the PwDs’ care stakeholders may enable a stronger relationship between them, facilitate a more coordinated care plan, and increase the feelings of empowerment in the informal caregivers. International Registered Report Identifier (IRRID): DERR1-10.2196/13280

22 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
CBClemens Becker
Clemens Becker
TETobias Eckert
Tobias Eckert
Jochen KlenkJochen Klenk
Jochen Klenk
CJCarl-Philipp Jansen
Carl-Philipp Jansen
MBMartin Aursand Berge
Martin Aursand Berge
AMAnna Marcuzzi
Anna Marcuzzi
Background/Objectives: The burden of disease caused by fragility fractures, and hip fractures in particular, is significant both from a personal and a societal perspective. Digital technologies such as wearable devices now allow a real-world assessment of walking and physical mobility, describing temporal and spatial measures. Built on a transparent technical validation, the Mobilise-D consortium validated a set of digital mobility outcomes (DMOs) alongside a longitudinal Clinical Validation Study (CVS). This article provides a description of DMOs along with supervised mobility assessment and patient-reported outcomes collected at entry of the CVS study in a sample of home-dwelling participants with a proximal femoral fracture (PFF) recruited within one year from surgery. Methods: Participants who underwent surgical treatment for a low-energy PFF were recruited from five sites in three high-income European countries. The baseline visit encompassed a clinical assessment (~3 hours) and subsequent 7-day measurement of real-world mobility with a single wearable device. We categorized participants into four recovery phases according to the assessment time after surgery: acute phase (≤14 days after surgery, hospital stay), post-acute phase (15-42 days after surgery, mostly rehabilitation), extended recovery phase (43 – 182 days post-surgery, typically post-discharge at home) and long-term recovery phase (183 – 365 days post-surgery). All variables were reported descriptively for each phase using mean and standard deviation or median and 25th-75th percentile depending on their distribution. Results: We enrolled 564 PFF participants (66% women). The mean age was 77.5 (SD 9.6) years. Almost 90% of all participants (n=505) had a valid digital mobility assessment (wear time of >12 hours per day and at least 3 valid days). DMO domains such as amount (e.g. number of steps), pace (e.g. walking speed) and pattern (bout distribution) demonstrated large differences across phases. Conclusions: The observed variation in walking amount, pace and pattern across recovery phases indicate that DMOs provide a granular analysis of real-world mobility of hip fracture survivors. When confirmed by longitudinal analyses, including results on minimal important differences, the use of selected DMOs will provide a novel approach for monitoring, predictive modeling, prognosis, stratification and evaluation of clinical trials and hip fracture services.

18 April 2025 in Sensors
Verified
Journal Article
Open access
PDF file
HYHananeh Younesian
Hananeh Younesian
DSDavid Singleton
David Singleton
BVBeatrix Vereijken
Beatrix Vereijken
JGJudith Garcia-Aymerich
Judith Garcia-Aymerich
LRLynn Rochester
Lynn Rochester
Brian CaulfieldBrian Caulfield
Brian Caulfield
Wearable and lightweight devices facilitate real-world physical activity (PA) assessments. MX metrics, as a cut-point-free parameter, evaluate acceleration above which the most active X minutes are accumulated. It provides insights into the intensity of PA over specific durations. This study evaluated the association of MX metrics and clinical tests in older adults recovering from proximal femoral fracture (PFF). Analyses were conducted on the PFF cohort from the baseline assessment of the Mobilise-D project using an accelerometer-based device. Participants (N = 396) were categorized into four recovery groups: acute, post-acute, extended recovery, and long-term recovery. Mobility capacity was assessed through the 6 min walking test (6MinWT), Short Physical Performance Battery (SPPB), 4-m walking test (4MWT), and hand grip (HG) strength. Mobility perception was evaluated using the Late-Life Function and Disability Instrument (LLFDI). Eight MX metrics (M1–M90) were calculated using the GGIR package in R. Results showed a moderate to strong positive correlation between M1 and M30 and lower limb mobility capacity tests and mobility perception (Lower Extremity domains) particularly in the extended and long-term recovery groups. MX metrics can be used for measuring PA intensity among older adults recovering from PFF. Hence, MX metrics have a high potential for clinical use as personalized PA targets in PFF rehabilitation.

2 August 2026 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
GBGavin Brittain
Gavin Brittain
MLMichael Long
Michael Long
EBEllen Buckley
Ellen Buckley
CBClemens Becker
Clemens Becker
JBJoren Buekers
Joren Buekers
JGJudith Garcia-Aymerich
Judith Garcia-Aymerich
Background: Wearable devices can measure real-world mobility and generate metrics known as digital mobility outcomes (DMOs). For people with multiple sclerosis (pwMS), these DMOs have not been clinically validated. This study aimed to evaluate the construct (convergent, divergent, and known groups) validity of a comprehensive panel of 24 DMOs in pwMS. Methods: PwMS were recruited to the Mobilise-D Clinical Validation Study, which involved 7-days of real-world mobility monitoring with a lower-back-worn wearable device. DMOs of walking amount, pattern, pace, rhythm, and variability domains were assessed. Convergent validity was evaluated against established clinical constructs (Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk, Multiple sclerosis (MS) Walking Scale-12, and Patient-Determined Disease Steps) using a priori hypotheses. Divergent validity was tested against systolic blood pressure. Known-groups validity was assessed across three EDSS strata. An expert panel completed a standardised consensus process. Results: We included 556 participants: 65% women, mean (SD) age of 52.3 (10.7) years, and median (p25–p75) EDSS 5 (4–6). Convergent, divergent, and known-groups validity were supported for 19, 24, and 23 DMOs, respectively. Nineteen DMOs, covering all domains, reached consensus agreement. Conclusion: This study confirms the construct validity of 19 DMOs across all walking domains in pwMS, supporting their use in clinical research and practice. www.isrctn.com/ISRCTN12051706 .